Release time: 2024-12-09 Article source: 特科羅
On December 9, 2024, clinical-stage biopharmaceutical company Technoderma Medicines Inc. (hereinafter referred to as "Technoderma") officially announced that its topical ointment TDM-180935, a JAK1/Tyk2 dual-target inhibitor developed for atopic dermatitis and eczema, has recently received approval from NMPA (National Medical Products Administration) of China for its Phase I/Ia clinical trial application.
